Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Acute arterial baroreflex-mediated changes in plasma catecholamine concentrations in a chronic rat model of myocardial infarction.

Kawada T, Akiyama T, Li M, Zheng C, Turner MJ, Shirai M, Sugimachi M.

Physiol Rep. 2016 Aug;4(15). pii: e12880. doi: 10.14814/phy2.12880.

2.

Spironolactone Prevents Endothelial Nitric Oxide Synthase Uncoupling and Vascular Dysfunction Induced by β-Adrenergic Overstimulation: Role of Perivascular Adipose Tissue.

Victorio JA, Clerici SP, Palacios R, Alonso MJ, Vassallo DV, Jaffe IZ, Rossoni LV, Davel AP.

Hypertension. 2016 Sep;68(3):726-35. doi: 10.1161/HYPERTENSIONAHA.116.07911. Epub 2016 Jul 18.

3.

Chronic Heart Failure Clinical Practice Guidelines' Class 1-A Pharmacologic Recommendations: Start-to-End Synergistic Drug Therapy?

Abarquez RF Jr, Reganit PF, Chungunco CN, Alcover J, Punzalan FE, Reyes EB, Cunanan EL.

ASEAN Heart J. 2016 Mar 8;24:4. eCollection 2016 Mar.

4.

Mechanisms of Vascular Smooth Muscle Contraction and the Basis for Pharmacologic Treatment of Smooth Muscle Disorders.

Brozovich FV, Nicholson CJ, Degen CV, Gao YZ, Aggarwal M, Morgan KG.

Pharmacol Rev. 2016 Apr;68(2):476-532. doi: 10.1124/pr.115.010652. Review.

5.

From statistical significance to clinical relevance: A simple algorithm to integrate brain natriuretic peptide and the Seattle Heart Failure Model for risk stratification in heart failure.

AbouEzzeddine OF, French B, Mirzoyev SA, Jaffe AS, Levy WC, Fang JC, Sweitzer NK, Cappola TP, Redfield MM.

J Heart Lung Transplant. 2016 Jun;35(6):714-21. doi: 10.1016/j.healun.2016.01.016. Epub 2016 Jan 15.

PMID:
27021278
6.

The Different Therapeutic Choices with ARBs. Which One to Give? When? Why?

Dézsi CA.

Am J Cardiovasc Drugs. 2016 Aug;16(4):255-66. doi: 10.1007/s40256-016-0165-4. Review.

7.

Statistical Methods for Cardiovascular Researchers.

Moyé L.

Circ Res. 2016 Feb 5;118(3):439-53. doi: 10.1161/CIRCRESAHA.115.306305. Review.

PMID:
26846639
8.

Influence of angiotensin II receptor blocker combination tablet prescription on drug number and cost.

Teramachi H, Takahashi T, Tachi T, Noguchi Y, Nagasawa H, Ino Y, Mizui T, Goto C, Tsuchiya T.

SAGE Open Med. 2014 Dec 22;2:2050312114563318. doi: 10.1177/2050312114563318. eCollection 2014.

9.

Recent Patient Characteristics and Medications at Admission and Discharge in Hospitalized Patients With Heart Failure.

Arimura T, Miura S, Morito N, Shiga Y, Kitajima K, Morii J, Iwata A, Fujimi K, Yahiro E, Saku K.

J Clin Med Res. 2016 Feb;8(2):97-104. doi: 10.14740/jocmr2402w. Epub 2015 Dec 28.

10.

Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Terms of Major Cardiovascular Disease Outcomes in Elderly Patients: A Nationwide Population-Based Cohort Study.

Chien SC, Ou SM, Shih CJ, Chao PW, Li SY, Lee YJ, Kuo SC, Wang SJ, Chen TJ, Tarng DC, Chu H, Chen YT.

Medicine (Baltimore). 2015 Oct;94(43):e1751. doi: 10.1097/MD.0000000000001751.

11.

What can we do about exploratory analyses in clinical trials?

Moyé L.

Contemp Clin Trials. 2015 Nov;45(Pt B):302-10. doi: 10.1016/j.cct.2015.09.012. Epub 2015 Sep 25.

PMID:
26390962
12.

Pediatric heart failure: current state and future possibilities.

Rossano JW, Jang GY.

Korean Circ J. 2015 Jan;45(1):1-8. doi: 10.4070/kcj.2015.45.1.1. Epub 2015 Jan 26. Review.

13.

The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: results of the REVERSE study.

Gold MR, Daubert C, Abraham WT, Ghio S, St John Sutton M, Hudnall JH, Cerkvenik J, Linde C.

Heart Rhythm. 2015 Mar;12(3):524-30. doi: 10.1016/j.hrthm.2014.11.014. Epub 2014 Nov 15.

14.

A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure.

McMurray J, Packer M, Desai A, Gong J, Greenlaw N, Lefkowitz M, Rizkala A, Shi V, Rouleau J, Solomon S, Swedberg K, Zile MR, Andersen K, Arango JL, Arnold M, Bĕlohlávek J, Böhm M, Boytsov S, Burgess L, Cabrera W, Chen CH, Erglis A, Fu M, Gomez E, Gonzalez A, Hagege AA, Katova T, Kiatchoosakun S, Kim KS, Bayram E, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires F, Refsgaard J, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire I, Starling RC, Vinereanu D, Teerlink JR, Wong R; PARADIGM-HF Committees and Investigators.

Eur Heart J. 2015 Feb 14;36(7):434-9.

15.

The comparative efficacy and safety of the angiotensin receptor blockers in the management of hypertension and other cardiovascular diseases.

Abraham HM, White CM, White WB.

Drug Saf. 2015 Jan;38(1):33-54. doi: 10.1007/s40264-014-0239-7. Review.

16.

Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15,990 patients.

Hasvold LP, Bodegård J, Thuresson M, Stålhammar J, Hammar N, Sundström J, Russell D, Kjeldsen SE.

J Hum Hypertens. 2014 Nov;28(11):663-9. doi: 10.1038/jhh.2014.43. Epub 2014 Jun 26.

17.

Efficacy and Tolerability of Nilvadipine in Combination with an Angiotensin II Receptor Antagonist in Patients with Essential Hypertension: A Multicenter, Open-Label, Uncontrolled Study.

Noda K, Ideishi M, Tashiro E, Nakashima Y, Imamura M, Seki M, Fujino M, Sou T, Kohara M, Kanaya H, Saku N, Kamei R, Yamasaki M, Sakai H, Gondo N, Saku K.

Curr Ther Res Clin Exp. 2003 Mar;64(3):151-66. doi: 10.1016/S0011-393X(03)00025-0.

19.

Angiotensin receptor antagonists to prevent sudden death in heart failure: does the dose matter?

Francia P, Palano F, Tocci G, Adduci C, Ricotta A, Semprini L, Caprinozzi M, Balla C, Volpe M.

ISRN Cardiol. 2014 Feb 6;2014:652421. doi: 10.1155/2014/652421. eCollection 2014. Review.

20.

Pharmacotherapy to reduce arrhythmic mortality.

Vora A, Kulkarni S.

Indian Heart J. 2014 Jan-Feb;66 Suppl 1:S113-9. doi: 10.1016/j.ihj.2013.12.049. Epub 2014 Jan 21. Review.

Items per page

Supplemental Content

Write to the Help Desk